- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04129034
Safety and Initial Feasibility of Using the Neurolyser XR Device for the Treatment of Axial Chronic Low Back Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design: Prospective, single arm
Timeline: six month enrollment period and 6 months follow-up period.
Sites: The study will be conducted at five sites in Canada: McGill University, Toronto Western, Silver Medical Group, Precision Sport & Spine, Kinetix Integrated Orthopaedic & Regenerative Medicine
Study population: Thirty adult patients diagnosed with facet related low back pain.
Primary study objective: Safety and efficacy of the Neurolyser XR for the treatment of chronic low back pain secondary to zygapophyseal joint syndrome.
Safety is measured by the incidence and severity of treatment related adverse events.
Efficacy is measured by the changes in pain severity at the treatment area, using a numerical rating scale (NRS), of 0 to 10 between baseline and 6 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, BC V6K 2E4
- Kinetix Medicine
-
-
Ontario
-
Oakville, Ontario, Canada, L6L 1H5
- Precision Sport & Spine
-
Toronto, Ontario, Canada, M3H 5S4
- Silver Medical Group
-
Toronto, Ontario, Canada, M5T 2S8
- Toronto Western
-
-
Quebec
-
Montréal, Quebec, Canada, H3G 1A4
- Alan Edwards Pain Management Unit - Montreal General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult male and females >55 years of age legally able and willing to participate in the study and come for follow-up visits
- Able and willing to fill the research questionnaires and to communicate with investigator and research team
- Patient with bilateral or unilateral low back pain of > 6 months duration
- Patients whose back pain is alleviated by recumbency or comfortable sitting position
- Patients presenting with a) a positive (>70% pain relief) to a previous, single or double, L1 to L5 lumbar medial branch block (within the last 12 months) and / or b) with a positive (>70% pain relief lasting more than 6 months) to a previous lumbar facet thermal radiofrequency denervation.
- Average pain score of 6 or higher in the last month, (on 0-10 scale).
Exclusion Criteria:
- Pregnant or breastfeeding patient
- Patients younger than 55 or older than 85 years
- Patients presenting with neurological deficits (including lumbosacral radiculopathy but not solitary radicular pain).
- Patients with history of lumbosacral spine surgery excluding previous lumbar radiofrequency neurotomy
- Patients who have had lumbar radiofrequency neurotomy in the past 6 months
- Patients with the presence of metal hardware or other foreign objects at the lumbosacral spine
- Patients with history of lumbar spine pathology that may increase procedural risk and / or influence symptoms and / or generate unrelated adverse event, (per the discretion of the study PI)
- Patients unable to understand and complete the research questionnaires in the official language used within the particular sites' location.
- Patients presenting with any severe medical condition preventing the patient from safely and effectively being treated in the study or reporting study outcome per PI decision.
- Patient with extensive scarring of the skin and tissue overlying the treatment area.
- Patients enrolled in or planned to be enrolled in another clinical trial during the duration of this research project
- Any patients with an uncontrolled coagulopathy
- Patients with known osteoporosis with absolute risk of spinal fracture of >10% over 10 years will be excluded
- Any patients with a history of malignant disease in the past five years
- Patients with rheumatologic diseases causing spine pain that are currently receiving active treatment including steroids, disease modifying drugs, biological agents or immunosuppressants.
- Patients known for concomitant psychiatric disorders, excluding mood disorders.
- Patients presenting with concomitant mood disorders (deemed severe by the research physician).
- Patients with a first-degree family member already enrolled in this study.
- Patient who is scheduled for any interventional/surgical procedure within 3 months from screening date
- Patients diagnosed with co-morbid multifocal chronic pain (e.g., fibromyalgia)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment
Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
|
Non-Invasive Thermal Ablation of the Medial Branch Nerves
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NRS
Time Frame: Time Frame: Base line, 2 days 1, 2 & 4 weeks, 3 & 6 months after procedure
|
Change in average pain score as measured by a numeric rating scale from 0 (no pain) to 10, worst possible pain
|
Time Frame: Base line, 2 days 1, 2 & 4 weeks, 3 & 6 months after procedure
|
Procedure and Device Safety at six months as measured by measured by the incidence and severity of treatment related adverse events
Time Frame: Time Frame: 6 months after procedure
|
Safety will be measured by the incidence and severity of treatment related adverse events
|
Time Frame: 6 months after procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oswestry Disability Index (ODI)
Time Frame: Time Frame: Base line, 1, & 4 weeks, 3 & 6 months after procedure
|
Low Back Pain Questionnaire (Range: 0% to 100%)
|
Time Frame: Base line, 1, & 4 weeks, 3 & 6 months after procedure
|
Patient Global Impression of Change (PGIC)
Time Frame: Time Frame: Base line, 1, & 4 weeks, 3 & 6 months after procedure
|
Patient Global Impression of Change (Range: 1 to 7)
|
Time Frame: Base line, 1, & 4 weeks, 3 & 6 months after procedure
|
Lesion Size
Time Frame: 2 days post procedure
|
Lesion size and location as shown in MRI Image, 2 days post treatment.
|
2 days post procedure
|
Short Form 12 (SF-12)
Time Frame: Time Frame: Base line, 1, & 4 weeks, 3 & 6 months after procedure
|
A multipurpose short form survey with 12 questions (Range: 0 to 100)
|
Time Frame: Base line, 1, & 4 weeks, 3 & 6 months after procedure
|
Procedure and Device Safety as measured by measured by the incidence and severity of treatment related adverse events
Time Frame: Time Frame: Base line, Procedure day, 2 days 1, 2 & 4 weeks, 3 & 6 months after procedure
|
Safety will be measured by the incidence and severity of treatment related adverse events
|
Time Frame: Base line, Procedure day, 2 days 1, 2 & 4 weeks, 3 & 6 months after procedure
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LBP-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Facet Syndrome of Lumbar Spine
-
Complejo Hospitalario Universitario de GranadaUnknownFacet Joint Pain | Facet Syndrome of Lumbar Spine | Facet Joints; DegenerationSpain
-
FUSMobile Inc.RambamCompletedFacet Syndrome of Lumbar SpineIsrael
-
Mansoura UniversityTanta UniversityCompletedFacet Syndrome of Lumbar SpineEgypt
-
Military University Hospital, PragueUniversity Hospital, MotolRecruitingDegenerative Disc Disease | Back Pain Lower Back Chronic | Facet Joint Arthropathy | Facet Syndrome of Lumbar SpineCzechia
-
FUSMobile Inc.Active, not recruitingFacet Syndrome of Lumbar SpineUnited States
-
InGeneron, Inc.Sanford HealthRecruitingOsteoarthritis of Facet Joint of Lumbar SpineUnited States
-
Oznur UzunRecruitingLow Back Pain, Mechanical | Facet Syndrome of Lumbar SpineTurkey
-
Erasme University HospitalUnknownLow Back Pain | Chronic Low Back Pain | Facet Joint Pain | Facet Syndrome of Lumbar SpineBelgium
-
Jyväskylä Central HospitalCompletedInstability of Lumbar SpineFinland
-
Grant SandersUniversity of KentuckyCompletedSubluxation of Joint of Lumbar SpineUnited States
Clinical Trials on Neurolyser XR
-
FUSMobile Inc.Focused Ultrasound FoundationNot yet recruiting
-
FUSMobile Inc.RambamCompletedFacet Syndrome of Lumbar SpineIsrael
-
FUSMobile Inc.Active, not recruitingFacet Syndrome of Lumbar SpineUnited States
-
Eisai Inc.Terminated
-
UCB PharmaCompletedEpilepsyUnited States, Poland, Mexico, Russian Federation
-
Supernus Pharmaceuticals, Inc.Completed
-
Coopervision, Inc.CompletedMyopia | HyperopiaUnited States, Canada
-
Envisia TherapeuticsCompletedGlaucoma and Ocular HypertensionUnited States
-
Upsher-Smith LaboratoriesRecruitingMigraine DisordersUnited States
-
Swiss Federal Institute of Sport MagglingenUnknownBone Age AssessmentSwitzerland